Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers — a cohort study using the Clinical Practice Research Datalink

Abstract

Overall, no differences in risk were observed in the main cohort analyses comparing Olm initiators with patients initiating therapy with other ARBs; however, HRs were marginally increased for all study endpoints which compared high-dose subgroups, suggesting potential increased risk may be associated with high-dose Olm. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.